SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Jeffrey Su, Ph.D., the Chief Operating Officer of Sorrento
Therapeutics, Inc. (the Company), resigned from the Company
effective June 30, 2017 in order to pursue other opportunities.
| Item 7.01. | Regulation FD Disclosure. |
On June 29, 2017, the Company issued a press release announcing
that the U.S. Food and Drug Administration has authorized the
Companys Investigational New Drug application for Resiniferatoxin
(RTX), a non-opioid, TRPV1 agonist that selectively targets
afferent nerve activation involved in chronic pain states. A copy
of the press release is furnished herewith as Exhibit 99.1 to
this Current Report on Form 8-K.
The information contained in this Item 7.01 and Exhibit 99.1
furnished as part of Item 9.01 of this Current Report on Form 8-K
is being furnished and shall not be deemed filed for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference
into any registration statement or other filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference to such
filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| 99.1 | Press release dated June 29, 2017. |
Sorrento Therapeutics, Inc. ExhibitEX-99.1 2 v470046_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain SAN DIEGO,…To view the full exhibit click here About SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE)
Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.
